Woodstock Corp Sells 505 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Woodstock Corp trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.8% in the 4th quarter, HoldingsChannel reports. The firm owned 4,655 shares of the biopharmaceutical company’s stock after selling 505 shares during the period. Woodstock Corp’s holdings in Regeneron Pharmaceuticals were worth $3,316,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Fairfield Financial Advisors LTD bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $39,000. Finally, Itau Unibanco Holding S.A. bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $42,000. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on REGN shares. Bank of America reiterated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Piper Sandler decreased their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.5 %

Shares of NASDAQ REGN opened at $693.23 on Friday. The stock has a market capitalization of $76.18 billion, a P/E ratio of 17.15, a PEG ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The business’s 50 day moving average is $744.16 and its two-hundred day moving average is $954.41. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.